Ann: Change in substantial shareholder interest, page-88

First 88 Last

Share
Profile

Follow
riskyrider

2,416 Posts.

302

10/07/19

13:39

Post #: 39456619
Share

Originally posted by harvett: ↑

I was informed by an outside source of the company that Paul Hopper had stopped selling and was being offered a deal to buy out of the market. James in his usually professional manner gave nothing away other than they were working on protecting the shareholders best interest. The same source told me Paul Hopper stopped being a consultant for KZA after only two months and went their separate ways because of a disagreement on how the company should run the trials and other issues. He then sold back in 2017 over 18 months. Death by a thousands cuts. This time he was brought out before to much damage was done.

I did the leg work, got the information end of story. I believe there was a lot of pressure put on management to sort out the PH selling well there was on my behalf at least and by many other investors and they came to the rescue.

Globalsat was nothing more than a brokerage company to pay to get the license. The milestone payments was the minimum.....I REPEAT THE MINIMUM we had to pay to get the licence over the line. Paul Hopper I believe IMHO wanted a whole lot more......a lot more. And that is part of the story we will never know. And I have probably said too much already.

Expand

That is good work buddy but maybe too good.

I think you should check out what insider trading is. I mean you knew it was not generally available and that it may affect the SP yeah?

KZA Price at posting: 43.0¢ Sentiment: Hold Disclosure: Held
2 Upvote

1 Great analysis

Reply

Top Stories

EEG

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

3DA

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

IRX

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

GDM

Banshee's historic trenches prove rich in antimony and gold for GDM

CLE

Cyclone signs MOU with Vale for development of Iron Bear play

BNL

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

HotCopper Highlights: Your most watched stocks for Week 46, 2024

CUF

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

First 88 Last

Add KZA (ASX) to my watchlist

Ann: Change in substantial shareholder interest, page-88

Top Stories

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

Banshee's historic trenches prove rich in antimony and gold for GDM

Cyclone signs MOU with Vale for development of Iron Bear play

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

HotCopper Highlights: Your most watched stocks for Week 46, 2024

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

Featured News